Ticker LaunchReverse merger · Completed · PDSB
PDS Biotechnology Corporation
Reverse merger with Edge Therapeutics, Inc.
PDS Biotechnology Corporation merged into Edge Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company, in a reverse merger that takes the private company public. The deal was announced on Nov 26, 2018 and closed on Mar 15, 2019. The combined company trades as PDS Biotechnology Corporation (PDSB) on Nasdaq.
PDS Biotechnology is a clinical-stage immunotherapy company developing cancer treatments, including Versamune-based products for head and neck, cervical, anal, prostate and breast cancers. It became public by merging with Edge Therapeutics.
- Status
- Completed
- Private company
- PDS Biotechnology Corporation
- Public company
- Edge Therapeutics, Inc.
- Public company business before
- Nasdaq-listed biopharmaceutical company
- Announced
- Nov 26, 2018
- Closed
- Mar 15, 2019
- Combined company
- PDS Biotechnology Corporation (PDSB)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Form 8-K (completion of acquisition) Mar 18, 2019
- Press release (Exhibit 99)
- Form 8-K (merger agreement) Nov 26, 2018
- Press release (merger announcement)
- All filings on EDGAR CIK 1472091
Other completed reverse mergers
- Oncotelic, Inc.into Mateon Therapeutics, Inc. · Apr 22, 2019
- Immunic AG (German private company)into Vital Therapies, Inc. · Apr 12, 2019
- Gadsden Growth Properties, Inc.into FC Global Realty Incorporated · Apr 5, 2019
- X4 Therapeutics, Inc.into Arsanis, Inc. · Mar 13, 2019
- OWP Ventures, Inc.into Punto Group, Corp. (One World Pharma, Inc.) · Feb 21, 2019
- Lovego Holdings Limitedinto Quintec Corp (Love International Group) · Feb 11, 2019